Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

E2000000

Ethionamide

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2-Ethyl-4-pyridinecarbothioamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C8H10N2S
CAS Number:
536-33-4
Molecular Weight:
166.24
MDL number:
MFCD00057361
UNSPSC Code:
41116107
PubChem Substance ID:
329799023
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

ethionamide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCc1cc(ccn1)C(N)=S

InChI

1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)

InChI key

AEOCXXJPGCBFJA-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ethionamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H302,H361

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[ROLE OF ETHIONAMIDE IN THE DETERMINISM OF NEUROLOGIC COMPLICATIONS OCCURRING DURING ANTITUBERCULAR TREATMENTS].
G BROUET et al.
La Revue du praticien, 14, 289-307 (1964-01-21)
Kerstin A Wolff et al.
Expert review of anti-infective therapy, 10(9), 971-981 (2012-10-31)
Antifolates inhibit de novo folate biosynthesis, whereas ethionamide targets the mycolate synthetic pathway in Mycobacterium tuberculosis. These antibiotics are effective against M. tuberculosis but their use has been hampered by concerns over toxicity and low therapeutic indexes. With the increasing
Tamao Nakashita et al.
Kekkaku : [Tuberculosis], 81(12), 731-735 (2007-01-24)
Cases of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with tuberculosis have been reported, however, in most of these cases, tuberculosis disease is miliary or severe. Here we report the first case of SIADH induced by ethionamide (TH).
Ethionamide.
Tuberculosis (Edinburgh, Scotland), 88(2), 106-108 (2008-05-20)
Nuno Vale et al.
Current drug metabolism, 14(1), 151-158 (2012-12-12)
Ethionamide (ETH) is an important second-line antituberculosis drug used for the treatment of patients infected with multidrug-resistant Mycobacterium. Although ETH is a structural analogue of isoniazid (INH), both are pro-drugs that need to be activated by mycobacterial enzymes to exert
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service